LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.
Metrics to compare | LIDDS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIDDSPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −9.6x | −0.5x | |
PEG Ratio | −0.01 | −0.20 | 0.00 | |
Price/Book | 2.3x | 6.7x | 2.6x | |
Price / LTM Sales | 833.9x | 42.7x | 3.3x | |
Upside (Analyst Target) | - | 8.1% | 43.4% | |
Fair Value Upside | Unlock | 6.5% | 7.1% | Unlock |